BR0113649A - Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres - Google Patents
Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheresInfo
- Publication number
- BR0113649A BR0113649A BR0113649-6A BR0113649A BR0113649A BR 0113649 A BR0113649 A BR 0113649A BR 0113649 A BR0113649 A BR 0113649A BR 0113649 A BR0113649 A BR 0113649A
- Authority
- BR
- Brazil
- Prior art keywords
- testosterone
- kits
- combinations
- mammal
- compositions
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 10
- 229960003604 testosterone Drugs 0.000 title abstract 5
- 150000003431 steroids Chemical class 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 abstract 4
- 206010002261 Androgen deficiency Diseases 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229960001566 methyltestosterone Drugs 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/651,777 US6503894B1 (en) | 2000-08-30 | 2000-08-30 | Pharmaceutical composition and method for treating hypogonadism |
| US70375300A | 2000-11-01 | 2000-11-01 | |
| US29239801P | 2001-05-21 | 2001-05-21 | |
| PCT/US2001/027199 WO2002017967A1 (en) | 2000-08-30 | 2001-08-29 | Method of increasing testosterone and related steroid concentrations in women |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0113649A true BR0113649A (pt) | 2004-07-20 |
Family
ID=27404127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0113649-6A BR0113649A (pt) | 2000-08-30 | 2001-08-29 | Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1322336B1 (https=) |
| JP (1) | JP2004507511A (https=) |
| KR (1) | KR20030048021A (https=) |
| CN (1) | CN100349572C (https=) |
| AU (2) | AU2001285367B2 (https=) |
| BR (1) | BR0113649A (https=) |
| CA (1) | CA2419573C (https=) |
| DK (1) | DK1322336T3 (https=) |
| ES (1) | ES2423899T3 (https=) |
| IL (2) | IL154693A0 (https=) |
| MX (1) | MXPA03001859A (https=) |
| NO (1) | NO334991B1 (https=) |
| NZ (1) | NZ536633A (https=) |
| PL (1) | PL360992A1 (https=) |
| PT (1) | PT1322336E (https=) |
| WO (1) | WO2002017967A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| ATE485837T1 (de) | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| IL163981A0 (en) * | 2002-03-15 | 2005-12-18 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method fortreating depression |
| HU230920B1 (hu) * | 2002-03-15 | 2019-03-28 | Besins Healthcare Luxembourg Sarl | Depresszió kezelésére szolgáló androgén gyógyászati készítmények |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
| AU2003240299B2 (en) * | 2002-06-25 | 2008-01-31 | Acrux Dds Pty. Ltd. | Metastable pharmaceutical compositions |
| AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
| US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| ATE534373T1 (de) | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| EP1868437A4 (en) * | 2005-04-12 | 2009-08-05 | Unimed Pharmaceuticals Inc | METHOD FOR TREATING OR PREVENTING BONE REMOVAL OR OSTEOPOROSIS |
| EP1868590A4 (en) * | 2005-04-13 | 2012-08-29 | Unimed Pharmaceuticals Inc | PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| KR20130114229A (ko) | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | 경피 약물 전달 방법 및 조성물 |
| CA2610708C (en) * | 2005-06-03 | 2013-10-08 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
| GEP20125432B (en) | 2005-10-12 | 2012-03-26 | Unimed Pharmaceuticals Llc | Improved testosterone gel and use thereof |
| CN101426475A (zh) | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
| EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
| CN102711554B (zh) | 2009-12-23 | 2014-10-29 | 高露洁-棕榄公司 | 口腔护理系统 |
| PH12012500882A1 (en) | 2009-12-23 | 2013-01-07 | Colgate Palmolive Co | Oral care system, kit and method |
| KR101528395B1 (ko) | 2009-12-23 | 2015-06-11 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템 |
| KR101513342B1 (ko) | 2009-12-23 | 2015-04-17 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템 |
| EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF |
| WO2020010205A1 (en) | 2018-07-05 | 2020-01-09 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
| AU2021216630A1 (en) * | 2020-02-05 | 2022-09-22 | Neurocrine UK Limited | Testosterone containing pharmaceutical composition |
| CN115754070B (zh) * | 2022-11-24 | 2025-11-25 | 深圳市第二人民医院(深圳市转化医学研究院) | 同时测定血液中总睾酮和游离睾酮含量的方法及试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| SK286051B6 (sk) * | 1993-01-19 | 2008-02-05 | Endorecherche Inc. | Použitie prekurzora pohlavného steroidu na prípravu liečiva na prevenciu alebo liečenie znížených alebo nevyrovnaných koncentrácií pohlavných steroidov |
| US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
| DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| AU6265998A (en) * | 1997-02-07 | 1998-08-26 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
| US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
| JP4139860B2 (ja) * | 1997-11-10 | 2008-08-27 | ストラカン インターナショナル リミティッド | 浸透増強および刺激減少システム |
-
2001
- 2001-08-29 AU AU2001285367A patent/AU2001285367B2/en not_active Expired
- 2001-08-29 ES ES01964525T patent/ES2423899T3/es not_active Expired - Lifetime
- 2001-08-29 CA CA002419573A patent/CA2419573C/en not_active Expired - Lifetime
- 2001-08-29 KR KR10-2003-7003111A patent/KR20030048021A/ko not_active Ceased
- 2001-08-29 MX MXPA03001859A patent/MXPA03001859A/es active IP Right Grant
- 2001-08-29 AU AU8536701A patent/AU8536701A/xx active Pending
- 2001-08-29 EP EP01964525.8A patent/EP1322336B1/en not_active Expired - Lifetime
- 2001-08-29 PT PT1964525T patent/PT1322336E/pt unknown
- 2001-08-29 WO PCT/US2001/027199 patent/WO2002017967A1/en not_active Ceased
- 2001-08-29 DK DK01964525.8T patent/DK1322336T3/da active
- 2001-08-29 BR BR0113649-6A patent/BR0113649A/pt not_active Application Discontinuation
- 2001-08-29 JP JP2002522940A patent/JP2004507511A/ja active Pending
- 2001-08-29 NZ NZ536633A patent/NZ536633A/xx not_active IP Right Cessation
- 2001-08-29 IL IL15469301A patent/IL154693A0/xx unknown
- 2001-08-29 PL PL01360992A patent/PL360992A1/xx not_active Application Discontinuation
- 2001-08-29 CN CNB018164331A patent/CN100349572C/zh not_active Expired - Lifetime
-
2003
- 2003-02-28 NO NO20030954A patent/NO334991B1/no not_active IP Right Cessation
- 2003-02-28 IL IL154693A patent/IL154693A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL154693A0 (en) | 2003-09-17 |
| DK1322336T3 (da) | 2013-07-15 |
| AU8536701A (en) | 2002-03-13 |
| EP1322336A1 (en) | 2003-07-02 |
| NO20030954D0 (no) | 2003-02-28 |
| CN100349572C (zh) | 2007-11-21 |
| WO2002017967A1 (en) | 2002-03-07 |
| PL360992A1 (en) | 2004-09-20 |
| NO334991B1 (no) | 2014-08-18 |
| ES2423899T3 (es) | 2013-09-25 |
| MXPA03001859A (es) | 2004-05-21 |
| CA2419573A1 (en) | 2002-03-07 |
| NO20030954L (no) | 2003-04-28 |
| NZ536633A (en) | 2006-03-31 |
| KR20030048021A (ko) | 2003-06-18 |
| PT1322336E (pt) | 2013-08-05 |
| EP1322336B1 (en) | 2013-07-03 |
| JP2004507511A (ja) | 2004-03-11 |
| HK1061804A1 (zh) | 2004-10-08 |
| IL154693A (en) | 2010-04-15 |
| CN1466467A (zh) | 2004-01-07 |
| HK1115537A1 (en) | 2008-12-05 |
| AU2001285367B2 (en) | 2006-05-18 |
| CA2419573C (en) | 2007-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0113649A (pt) | Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres | |
| CY1110085T1 (el) | Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες | |
| BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
| BR0011740A (pt) | Administração de esteróides androgênicos não-orais a mulheres | |
| BR0107535A (pt) | Uso de carotenóides e forma de dosagem unitária destes | |
| BR9910851A (pt) | Composição de tratamento para os cabelos. | |
| BRPI0110914B8 (pt) | 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica' | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| BR0212374A (pt) | Oxintomodulina para a prevenção ou para o tratamento do excesso de peso | |
| BR0214184A (pt) | Composições que contêm óleos que possuem gravidade especìfica mais alta que a gravidade especìfica da água | |
| PT836506E (pt) | Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio | |
| DZ3221A1 (fr) | Nouvelles compositions estro-progestatives topiques a effet systemique | |
| BR9812134A (pt) | Composição farmacêutica para tratamento de dismenorréia e parto prematuro | |
| BR0206639A (pt) | Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares | |
| BR0214716A (pt) | Contraceptivos para prevenção de gravidez e diminuição de sintomatologia pré-menstrual | |
| CL2004000026A1 (es) | Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. | |
| BR0012081A (pt) | Composição farmacêutica compreendendo sulfato de morfina e gluconato de sódio, método para preparar dita composição e para provocar resposta anestésica ou analgésica num mamìfero | |
| BR0308584A (pt) | Composição farmacêutica androgênica e método para tratamento de depressão | |
| BR0111141A (pt) | Métodos de tratar a deficiência de androgênio em homens e de tratar distúrbios relacionados com menopausa masculina nos homens | |
| BR0114665A (pt) | Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio | |
| BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
| BR9814284A (pt) | Composições e métodos para regulação de fagocitose e expressão de icam-1 | |
| BR0014979A (pt) | Composição hormonal e sua utilização | |
| BR0104390A (pt) | Método para redução de inflamação e eritema | |
| BR0113667A (pt) | Tratamento de disfunção urinária |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: UNIMED PHARMACEUTICALS, LLC (US) Free format text: ALTERADO DE: UNIMED PHARMACEUTICALS, INC. |
|
| B25G | Requested change of headquarter approved |
Owner name: UNIMED PHARMACEUTICALS, LLC (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090070515/RJ DE 21/07/2009. |
|
| B25A | Requested transfer of rights approved |
Owner name: UNIMED PHARMACEUTICALS, LLC (US) , LABORATOIRES BE Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: UNIMED PHARMACEUTICALS, LLC |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |